AHA Scientific Sessions 2023 Late-Breaking Science Coverage
Published: 30 October 2023
-
Views:
2218
-
Likes:
7
-
Views:
2218
-
Likes:
7
-
Up Next -
12m 34sPart 1 | Session 2 View from the Thoraxcenter: AHA 23 Late-breaking Science Preview
-
22m 30sPart 2 | Session 1 AHA 23 Late-Breaker Discussion: The ARIES HM3 Clinical Trial -
14m 14sPart 2 | Session 2 AHA 23 Late-Breaker Discussion: The DAPA-MI Trial -
19m 41sPart 2 | Session 3 AHA 23 Late-Breaker Discussion: Hypertension Treatment in Nigeria Program -
21m 35sPart 2 | Session 4 AHA 23 Late-Breaker Discussion: The SELECT Trial
-
3m 11s -
6m 55sPart 3 | Session 2 ECLS-SHOCK: Impact of Cardiac Arrest on the Efficacy of ECLS Patients -
5m 4s -
3m 54sPart 3 | Session 4 Nicotinamide Riboside in PAD for Improved Walking -
8m 27sPart 3 | Session 5 SPECIAL: Ultrasound-assisted Thrombolysis Vs Pulmonary Embolectomy for PE -
4m 59s -
10m -
6m 55s -
10m 9sPart 3 | Session 9 JEWEL-IDE: Jewel P-WCD in Pts at High Risk of Cardiac Arrest -
4m 59s -
5m 4s
-
7m 3sPart 4 | Session 1 Preventive Cardiology Highlights in 2023 -
10m 59sPart 4 | Session 2 3 Trials That Will Change My Practice With Dr Parwani -
7m 20sPart 4 | Session 3 3 Trials That Will Change My Practice With Dr Itchhaporia
-
2mPart 5 | Session 1 Solving Problems with Dr Pugazhendi Vijayaraman -
1m 36sPart 5 | Session 2 Advice for Early-Career Researchers With Dr Demilade Adedinsewo -
39sPart 5 | Session 3 Making a Difference with Dr Alexander Fanaroff
Overview
Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.
In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.
Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.
Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.
Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.
More from this programme
Part 1
View from the Thoraxcenter
In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23.
Part 2
Late-Breaker Discussions with Harriette Van Spall
Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.
Part 3
Expert Interviews
Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.
Part 4
Highlights
About the episode
What's hot at #AHA23?
Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023.
They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.
Trials Covered
00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack
06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial
12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial:
16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes
We value your opinion! Share your feedback by commenting on this page or sending us an email at info@radcliffe-group.com.
Faculty Biographies
Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Comments